Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease
Background. Hypocalcaemia is increasingly recognized as a complication of denosumab use in Chronic Kidney Disease (CKD) patients with osteoporosis. Despite Therapeutic Goods Administration (TGA) notifications in 2013, we have subsequently encountered several cases of denosumab-induced hypocalcaemia,...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Case Reports in Nephrology |
| Online Access: | http://dx.doi.org/10.1155/2018/7384763 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565163647041536 |
|---|---|
| author | Ryan Jalleh Gopal Basu Richard Le Leu Shilpanjali Jesudason |
| author_facet | Ryan Jalleh Gopal Basu Richard Le Leu Shilpanjali Jesudason |
| author_sort | Ryan Jalleh |
| collection | DOAJ |
| description | Background. Hypocalcaemia is increasingly recognized as a complication of denosumab use in Chronic Kidney Disease (CKD) patients with osteoporosis. Despite Therapeutic Goods Administration (TGA) notifications in 2013, we have subsequently encountered several cases of denosumab-induced hypocalcaemia, raising concern about lack of widespread awareness among prescribing practitioners. Aims. We reviewed the morbidity and healthcare intervention needs of CKD patients with hypocalcaemia attributed to denosumab. Methods. A retrospective case series of CKD patients with clinically significant hypocalcaemia after exposure to denosumab, encountered at the tertiary care referral hospital from December 2013 to February 2017, was undertaken. Results. Eight patients (52-85 years of age) with stage 4-5 CKD developed clinically significant hypocalcaemia (corrected calcium 1.45±0.21mmol/L) following denosumab therapy for osteoporosis. Seven of the eight patients required inpatient management with three patients requiring intravenous calcium replacement and cardiac monitoring in a high dependency unit. Our study also identified additional factors that could potentially contribute to hypocalcaemia such as lack of calcium supplementation, use of noncalcium based phosphate binders, absence of or use of lower doses of calcitriol supplementation, low vitamin D levels, concomitant treatment with loop diuretics, history of parathyroidectomy, or presence of acute medical illness. Conclusion. Multiple cases of severe hypocalcaemia in CKD patients following denosumab exposure were encountered after TGA warnings, resulting in considerable morbidity and intensive healthcare interventions in CKD patients. We advocate greater awareness amongst the medical profession, careful consideration before using denosumab in CKD patients, and close follow-up after administration to prevent morbidity. |
| format | Article |
| id | doaj-art-4e4e1406b28246059560f4393077ff02 |
| institution | Kabale University |
| issn | 2090-6641 2090-665X |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Nephrology |
| spelling | doaj-art-4e4e1406b28246059560f4393077ff022025-02-03T01:09:00ZengWileyCase Reports in Nephrology2090-66412090-665X2018-01-01201810.1155/2018/73847637384763Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney DiseaseRyan Jalleh0Gopal Basu1Richard Le Leu2Shilpanjali Jesudason3Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaCentral and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaCentral and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaCentral and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, South Australia, AustraliaBackground. Hypocalcaemia is increasingly recognized as a complication of denosumab use in Chronic Kidney Disease (CKD) patients with osteoporosis. Despite Therapeutic Goods Administration (TGA) notifications in 2013, we have subsequently encountered several cases of denosumab-induced hypocalcaemia, raising concern about lack of widespread awareness among prescribing practitioners. Aims. We reviewed the morbidity and healthcare intervention needs of CKD patients with hypocalcaemia attributed to denosumab. Methods. A retrospective case series of CKD patients with clinically significant hypocalcaemia after exposure to denosumab, encountered at the tertiary care referral hospital from December 2013 to February 2017, was undertaken. Results. Eight patients (52-85 years of age) with stage 4-5 CKD developed clinically significant hypocalcaemia (corrected calcium 1.45±0.21mmol/L) following denosumab therapy for osteoporosis. Seven of the eight patients required inpatient management with three patients requiring intravenous calcium replacement and cardiac monitoring in a high dependency unit. Our study also identified additional factors that could potentially contribute to hypocalcaemia such as lack of calcium supplementation, use of noncalcium based phosphate binders, absence of or use of lower doses of calcitriol supplementation, low vitamin D levels, concomitant treatment with loop diuretics, history of parathyroidectomy, or presence of acute medical illness. Conclusion. Multiple cases of severe hypocalcaemia in CKD patients following denosumab exposure were encountered after TGA warnings, resulting in considerable morbidity and intensive healthcare interventions in CKD patients. We advocate greater awareness amongst the medical profession, careful consideration before using denosumab in CKD patients, and close follow-up after administration to prevent morbidity.http://dx.doi.org/10.1155/2018/7384763 |
| spellingShingle | Ryan Jalleh Gopal Basu Richard Le Leu Shilpanjali Jesudason Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease Case Reports in Nephrology |
| title | Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease |
| title_full | Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease |
| title_fullStr | Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease |
| title_full_unstemmed | Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease |
| title_short | Denosumab-Induced Severe Hypocalcaemia in Chronic Kidney Disease |
| title_sort | denosumab induced severe hypocalcaemia in chronic kidney disease |
| url | http://dx.doi.org/10.1155/2018/7384763 |
| work_keys_str_mv | AT ryanjalleh denosumabinducedseverehypocalcaemiainchronickidneydisease AT gopalbasu denosumabinducedseverehypocalcaemiainchronickidneydisease AT richardleleu denosumabinducedseverehypocalcaemiainchronickidneydisease AT shilpanjalijesudason denosumabinducedseverehypocalcaemiainchronickidneydisease |